Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites.
about
Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidateMolecular dissection of the human antibody response to the structural repeat epitope of Plasmodium falciparum sporozoite from a protected donorThree decades of USAID investments in immunization through the child survival revolutionYellow fever 17D as a vaccine vector for microbial CTL epitopesStage-dependent localization of a novel gene product of the malaria parasite, Plasmodium falciparumPlasmodium vivax Controlled Human Malaria Infection - Progress and ProspectsThe March Toward Malaria VaccinesPfSPATR, a Plasmodium falciparum protein containing an altered thrombospondin type I repeat domain is expressed at several stages of the parasite life cycle and is the target of inhibitory antibodiesExpression of the Plasmodium falciparum immunodominant epitope (NANP)(4) on the surface of Salmonella enterica using the autotransporter MisLPhase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein.Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data.Isolation and serological characterization of a Plasmodium vivax recombinant antigen.Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the moleculeNatural antibody responses against the non-repeat-sequence-based B-cell epitopes of the Plasmodium falciparum circumsporozoite protein.Expression and immune recognition of the conserved MSP4 outer membrane protein of Anaplasma marginale.Type 1 CD4(+) T-cell help is required for induction of antipeptide multispecific cytotoxic T lymphocytes by a lipopeptidic vaccine in rhesus macaquesInduction of protective immune responses by immunization with linear multiepitope peptides based on conserved sequences from Plasmodium falciparum antigensAn unstable Th epitope of P. falciparum fosters central memory T cells and anti-CS antibody responses.Salmonella typhi flagella are potent inducers of proinflammatory cytokine secretion by human monocytes.Immunogenicity of well-characterized synthetic Plasmodium falciparum multiple antigen peptide conjugates.Roles of the amino terminal region and repeat region of the Plasmodium berghei circumsporozoite protein in parasite infectivityA modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hostsProgress toward a malaria vaccine: efficient induction of protective anti-malaria immunity.Multiple antigen peptide vaccines against Plasmodium falciparum malariaSusceptibility of different strains of mice to hepatic infection with Plasmodium berghei.Developmental biology of sporozoite-host interactions in Plasmodium falciparum malaria: implications for vaccine design.Successful human infection with P. falciparum using three aseptic Anopheles stephensi mosquitoes: a new model for controlled human malaria infection.Theoretical and practical aspects of antigenized antibodies.Continuation of chloroquine-susceptible Plasmodium falciparum parasitemia in volunteers receiving chloroquine therapy.Influence of preimmunization with tetanus toxoid on immune responses to tetanus toxin fragment C-guest antigen fusions in a Salmonella vaccine carrier.A conserved peptide sequence of the Plasmodium falciparum circumsporozoite protein and antipeptide antibodies inhibit Plasmodium berghei sporozoite invasion of Hep-G2 cells and protect immunized mice against P. berghei sporozoite challengeNYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.The immunological challenge to developing a vaccine to the blood stages of malaria parasites.Construction, expression, and immunogenicity of the Schistosoma mansoni P28 glutathione S-transferase as a genetic fusion to tetanus toxin fragment C in a live Aro attenuated vaccine strain of Salmonella.Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice.Restricted or absent immune responses in human populations to Plasmodium falciparum gamete antigens that are targets of malaria transmission-blocking antibodies.Synthetic peptide vaccine confers protection against murine malaria.Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopesPre-erythrocytic malaria vaccines: towards greater efficacy.Sporozoite neutralizing antibodies elicited in mice and rhesus macaques immunized with a Plasmodium falciparum repeat peptide conjugated to meningococcal outer membrane protein complex
P2860
Q24648408-6F139F09-AE90-413B-A04B-EEBC2BEAE669Q24798369-A811C7E3-BCC8-4027-A162-BCD8742FA99AQ26863426-61D57CF6-06D7-41EB-BFC7-2B12F0CB2A19Q27485204-61CCBF84-C72A-42D9-BFD2-5E6927AAD994Q27972741-76363353-2B8C-4136-B98E-9C712DC1F4C4Q28066456-BCD83906-079B-4CC7-B905-C5C06A519F2FQ28084325-39638378-AFAE-4127-AB76-7D2EB4B57E8DQ30043808-25DC9FC0-15A2-41DF-B042-3FB071CAEC10Q33183819-09A4EFF9-CA4B-4BF2-B82F-28FD056390E7Q33318466-A51E883C-D83B-4FED-B1BD-5060905A9489Q33521372-1346D430-1FE5-4D0D-8C11-521AB694C1E4Q33550482-29BBB7A8-2001-40B0-87A6-E16DCD94C8A4Q33554105-A4CDD158-A57D-451B-B58B-67823646C779Q33599748-C279D017-403E-4E03-A6C8-D679149F2D36Q33617329-C3D6A65C-86A9-49F8-8A0B-33E9FA420991Q33648495-B66E7C0F-5BAB-44C6-902E-8450AE8A8894Q33756304-87E394D9-403D-478E-89C7-45289AD5E613Q33830488-674FD247-CBF9-4F2B-B758-346E9DA92D1CQ33877245-821F7FE9-63EB-4226-9C98-047561338362Q34008562-50103D15-2BFA-47CD-A051-7504D0E401FCQ34185908-9369AA2B-B670-4C36-8320-BE5EF4E1CF88Q34261339-E658360A-0D16-415C-8577-B927948EE425Q34280935-A1AAA38B-9139-4C03-ABC5-2251C5E8550AQ34290800-EC4BD4AC-FAF7-4F3F-A1EE-5A2891D1EF61Q34543990-65926026-6247-4E0E-AF30-4BF2803184B6Q34573891-D990B68D-C861-42EF-A5C4-C55B4B7388B8Q34852105-278BBC20-1DA8-4C3C-B198-ED133651DD2EQ35180010-C0E93E90-3E51-4627-88D2-094F6B88F57FQ35252891-72876F58-7761-4D6A-84C4-60CAD8B145DBQ35422555-2DA46197-E701-42C4-9B5B-FC6585745FDBQ35449891-A2209DF8-D6B9-437C-B120-91FE280417BDQ35519418-3537F426-4768-4297-A602-ADF4D4DBA3DCQ35884247-DB9A4B1B-F8D1-4771-80F5-84549B12CDDAQ35904338-4BBA7752-0A19-45C2-95BA-E4794178D284Q36014035-850F78E1-1331-4B55-B7AB-F9059FAD4AF4Q36355913-202F0E94-BB1D-4AE6-9AB1-224BD7E16EFEQ36357591-FB38084A-97B1-4746-92AE-F3254E38ECC6Q36363602-0D1DCDCE-0FF3-4881-A1F5-44D43BF8A96BQ36403400-164C23CE-EAB6-4FD1-80E7-C5D1666D93E8Q36434929-BDF1E522-D3A5-4CCC-99C1-7B54851D0BA7
P2860
Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh-hant
name
Safety and immunogenicity in m ...... modium falciparum sporozoites.
@en
Safety and immunogenicity in m ...... modium falciparum sporozoites.
@nl
type
label
Safety and immunogenicity in m ...... modium falciparum sporozoites.
@en
Safety and immunogenicity in m ...... modium falciparum sporozoites.
@nl
prefLabel
Safety and immunogenicity in m ...... modium falciparum sporozoites.
@en
Safety and immunogenicity in m ...... modium falciparum sporozoites.
@nl
P2093
P356
P1433
P1476
Safety and immunogenicity in m ...... modium falciparum sporozoites.
@en
P2093
Cortesia M
Gillessen D
Herrington DA
Losonsky G
P2888
P304
P356
10.1038/328257A0
P407
P577
1987-07-01T00:00:00Z
P6179
1043517209